Suzhou Highfine Biotech Valuation

Q: What is the Fair Price of 301393 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

301393 (CN¥50.12) is trading above our estimate of [[fair value]] (CN¥18.03)

Is 301393 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301393 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301393 (CN¥50.12) is trading above our estimate of fair value (CN¥18.03)

Significantly Below Fair Value: 301393 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301393?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 301393. This is calculated by dividing 301393's market cap by their current preferred multiple.
What is 301393's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥5.56b

301393 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	10.7x
Enterprise Value/EBITDA	56x
PEG Ratio	1.1x

Price to Earnings Ratio vs Peers

How does 301393's PE Ratio compare to its peers?

The above table shows the PE ratio for 301393 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	58.1x
000411 Zhejiang Int'l GroupLtd	11.1x	n/a	CN¥5.8b
688553 Sichuan Huiyu Pharmaceutical	40.8x	n/a	CN¥6.2b
603718 Shanghai Hile Bio-Technology	87.3x	n/a	CN¥5.5b
002907 Chongqing Pharscin Pharmaceutical	93x	n/a	CN¥6.4b
301393 Suzhou Highfine Biotech	58.5x	51.0%	CN¥5.6b

Price-To-Earnings vs Peers: 301393 is expensive based on its Price-To-Earnings Ratio (58.5x) compared to the peer average (58.1x).

Price to Earnings Ratio vs Industry

How does 301393's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.5%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.5%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 301393 is expensive based on its Price-To-Earnings Ratio (58.5x) compared to the CN Pharmaceuticals industry average (31.6x).

Price to Earnings Ratio vs Fair Ratio

What is 301393's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301393 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	58.5x
Fair PE Ratio	46.5x

Price-To-Earnings vs Fair Ratio: 301393 is expensive based on its Price-To-Earnings Ratio (58.5x) compared to the estimated Fair Price-To-Earnings Ratio (46.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.